Allergologia et immunopathologia最新文献

{"title":"Tolerance induction for food allergy using immunoglobulin/histamine complex: A case report.","authors":"Hyuk Soon Kim, Geunwoong Noh","doi":"10.15586/aei.v54i4.1541","DOIUrl":"10.15586/aei.v54i4.1541","url":null,"abstract":"<p><p>Food allergy is defined as an immune-mediated adverse reaction to dietary proteins and is a major health problem with an increasing prevalence. Immunoglobulin/histamine complex (IHC) is an anti-allergy therapeutic that acts primarily by reducing histamine levels (histaminopexy). A 5-year-old male Korean patient with a food allergy was transferred for immunotherapy. Open food challenge (OFC) for wheat before treatment revealed positive reactions after challenge with 0.5g of wheat. Under a diagnosis of food allergy for wheat, allergic rhinitis, and atopic dermatitis, treatment with Histobulin^TM (Green Cross PD, Korea), an IHC preparation, was initiated. After 23 injections, the patient did not exhibit any adverse reaction after the intake of 60 g of wheat in the OFC. Specific IgE levels and skin reactivities for wheat also decreased after IHC therapy. A 40-year-old female Korean patient presented with severe generalized urticaria, severe itching, and even whole body prickling immediately after every intake of shrimp or crab over 10 years; she also had allergic rhinitis. Basic allergy lab and skin prick testing results showed no abnormal findings, but OFC for shrimp and raw crab (both at 0.5 g) produced generalized urticaria, rashes, and itching immediately after intake. Under a diagnosis of chronic urticaria, allergic rhinitis, and food allergy to crab and shrimp, IHC therapy was initiated. After 86 injections of Histobulin^TM, the patient did not show any allergy reaction to shrimp or crab after the intake of 10 g of raw shrimp or 10 g of raw crab. IHC treatment successfully induced food allergen tolerance in a nonallergen-specific manner.</p>","PeriodicalId":7536,"journal":{"name":"Allergologia et immunopathologia","volume":"54 4","pages":"135-143"},"PeriodicalIF":2.1,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148417939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of allergic diseases and attention-deficit/hyperactivity (ADHD) disorder in children: a large-scale cohort study.","authors":"Selçuk Sinan Çelik, Erdem Erkoyun, İdil Akay Hacı, Mehmet Şirin Kaya, Ali Emre Çetinkol, Yusuf Adnan Güçlü, Fatma Sibel Durak, Sultan Eser, Demet Can","doi":"10.15586/aei.v54i4.1555","DOIUrl":"https://doi.org/10.15586/aei.v54i4.1555","url":null,"abstract":"<p><strong>Background: </strong>The burden of attention-deficit/hyperactivity disorder (ADHD) has increased during the last few decades, as in allergic disorders. In some observational studies, ADHD has been linked to allergic diseases, but the evidence remains limited.</p><p><strong>Objective: </strong>The aim of this study was to investigate whether allergic disorders are associated with ADHD in a large cohort of patients.</p><p><strong>Material and methods: </strong>Data from this cohort were retrieved from 860,089 children aged 5-16 years, collected from the pediatric database of Health Services in İzmir, Turkey, between January 1, 2013 and December 31, 2023, and analyzed. The person-years and the association between allergic disorders (including respiratory, skin, and other allergies, such as food and drug allergies as well as anaphylaxis) and ADHD were estimated using relative risks.</p><p><strong>Results: </strong>The incidence of allergic disorders in the last 11 years was 7.9% (68,351 cases). Respiratory allergies (61,728; 6.8%) were the most common one, followed by skin allergies (7,152; 0.9%). The incidence of ADHD was determined as 5.3% and, as expected, was more common in boys (7.2%). The total number of patients with allergic diseases diagnosed prior to ADHD was 64,137 (7.5%), and the most common were respiratory allergies (57,905; 6.7%) and skin allergies (6,602; 0.8%). The other allergy group comprised 1,878 (0.2%) cases. The relative risk estimations showed a positive association between allergy groups and ADHD (relative risk [RR] 1.99, 95% Confidence Interval [CI] 1.96-2.02) for both genders.</p><p><strong>Conclusion: </strong>An association is observed between allergic disorders and ADHD. Understanding the link and relationship between allergic disorders and the development of ADHD will lead to earlier diagnosis and better treatment of allergic children with neurodevelopmental symptoms. To establish this association more robustly, further population-based cohorts are required.</p>","PeriodicalId":7536,"journal":{"name":"Allergologia et immunopathologia","volume":"54 4","pages":"20-29"},"PeriodicalIF":2.1,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148417681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Symptom and quality of life assessment during season undergoing pollen immunotherapy: single center study.","authors":"Hatice Irmak Çelik, Ragıp Dere, Çağrı Torun Özel, Ahmet Selmanoğlu, Zeynep Şengül Emeksiz, Emine Dibek Mısırlıoğlu","doi":"10.15586/aei.v54i4.1598","DOIUrl":"https://doi.org/10.15586/aei.v54i4.1598","url":null,"abstract":"<p><strong>Background: </strong>Allergic rhinitis (AR) is an IgE-mediated inflammatory condition of the nasal mucosa. Allergen immunotherapy (AIT) is the only treatment that can modify disease progression and provide long-term symptom control. This study evaluated symptom burden and health-related quality of life (HRQoL) during the pollen season in pediatric patients treated with subcutaneous pollen immunotherapy (SCIT).</p><p><strong>Material and methods: </strong>This prospective, cross-sectional study included children aged 6-18 years who received ≥12 months of AIT between 2014 and 2022. All had isolated pollen allergy and were treated with SCIT. Symptom control was assessed using the Total Nasal Symptom Score (TNSS) and Visual Analog Scale (VAS), while HRQoL was measured using PRQLQ or RQLQ depending on age. Patients were grouped by treatment duration: <36 months and ≥36 months.</p><p><strong>Results: </strong>Forty-seven patients completed questionnaires at least two pollen seasons after their final SCIT dose. Compared with the <36-month group, patients treated for ≥36 months showed significantly lower nasal and ocular symptoms (P < 0.001). Mean TNSS scores were lower (5.42 vs. 9.57, P = 0.018), and more patients had mild symptoms (60.6% vs. 21.4%, P = 0.003). Good symptom control (VAS < 2) was also more frequent (36.4% vs. 14.3%, P = 0.022). HRQoL scores (PRQLQ/RQLQ) were significantly better in the ≥36-month group, particularly in social and school functioning.</p><p><strong>Conclusion: </strong>SCIT duration ≥36 months is associated with improved symptom control and HRQoL during the pollen season, supporting guideline recommendations of at least 3 years of AIT in pediatric AR.</p>","PeriodicalId":7536,"journal":{"name":"Allergologia et immunopathologia","volume":"54 4","pages":"30-37"},"PeriodicalIF":2.1,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148417912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative analysis of seven standardised commercially available grass extracts for sublingual immunotherapy in liquid formulation.","authors":"Jenaro José Hernández-Peña, Clara Flores Infante, Andrea Vera Flores, Mónica Escorial, Beatriz Brotons Silvar, Flavia T Hernández","doi":"10.15586/aei.v54i4.1612","DOIUrl":"https://doi.org/10.15586/aei.v54i4.1612","url":null,"abstract":"<p><p>Sublingual immunotherapy with allergens requires high allergen doses to achieve the desired clinical efficacy. Given the current differences among products on the market, this study aims to compare seven therapeutic sublingual grass pollen extracts to quantify the Group 5 allergen concentrations, assess their biological activity and characterise allergenic profiles. The extracts were analysed by protein quantification (Bradford method), characterisation of the protein profile (SDS-PAGE) and determination of biological activity (ELISA inhibition and immunoblotting). Major allergens (Group 5) were also quantified using a sandwich ELISA. Differences were observed between the various allergenic extracts. Protein content ranged from 27 to 231 µg/mL, with Apioral Forte, SlitOne Ultra and Sublivac showing similar protein profiles. These extracts also displayed the highest biological activity, while the quantification of major Group 5 allergens was greatest in Apioral Forte, Sublivac and Tol Forte. The differences observed between extracts may have a relevant clinical impact. It is essential to have standardised, comparative analytical methods that allow specialists to select the most appropriate treatment.</p>","PeriodicalId":7536,"journal":{"name":"Allergologia et immunopathologia","volume":"54 4","pages":"105-113"},"PeriodicalIF":2.1,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148417604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of the efficacy and medication adherence of fluticasone propionate-salmeterol combination delivered via a capsule-based dry powder inhaler in asthmatic patients.","authors":"Özge Göktürk, Ayfer Utkusavaş, Murat Akıncı, Kurtuluş Aksu","doi":"10.15586/aei.v54i4.1704","DOIUrl":"10.15586/aei.v54i4.1704","url":null,"abstract":"<p><strong>Introduction: </strong>The primary treatment for asthma is inhaled medication, and therefore, regular patient follow-up significantly impacts treatment outcomes. This study aimed to retrospectively evaluate the efficacy of fluticasone-salmeterol combination treatment via a capsule-based dry powder inhaler and medication adherence at first and third months of treatment in asthmatic patients.</p><p><strong>Methods: </strong>This study is an observational study retrospectively examining the clinical data of asthma patients treated with RESPIRO-D capsule inhaler. The study population consisted of adult asthma patients requiring level 3 asthma treatment according to GINA criteria. Data, including baseline and follow-up clinical characteristics such as age, gender, smoking history, body mass index, comorbidities, pulmonary function test (PFT) values, asthma control test (ACT) scores, and Morisky Medication Adherence Scale-8 (MMAS-8) scores, were obtained by reviewing patient records. PFT, ACT scores, and MMAS-8 measurements were recorded and compared at three different time points (baseline, first month, third month) in asthmatic individuals treated with fluticasone-salmeterol capsule inhaler.</p><p><strong>Results: </strong>In all, 131 subjects were included in the study. Statistically significant increase was seen in all lung functions in spirometric measurements recorded at baseline and at first and third months of treatment. ACT scores of subjects were increased at first month of treatment compared to baseline and further increased at third month of treatment compared to 1st month of treatment. MMAS-8 did not change significantly at first and third months of treatment. None of the patients stopped treatment due to drug-related side effects.</p><p><strong>Conclusion: </strong>This study demonstrates that fluticasone-salmeterol capsule inhaler therapy can significantly improve symptom control and respiratory function in adult asthma patients.</p>","PeriodicalId":7536,"journal":{"name":"Allergologia et immunopathologia","volume":"54 4","pages":"114-119"},"PeriodicalIF":2.1,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148417683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Changing trends in aeroallergen sensitization: Evidence for gender-specific profiles.","authors":"Violeta Lokaj-Berisha, Besa Gacaferri Lumezi","doi":"10.15586/aei.v54i4.1675","DOIUrl":"https://doi.org/10.15586/aei.v54i4.1675","url":null,"abstract":"<p><strong>Background: </strong>Sex-related differences in allergic diseases are recognized; however, variation in aeroallergen sensitization patterns across clinical populations remains incompletely characterized.</p><p><strong>Objective: </strong>To examine sex-specific differences in sensitization profiles and polysensitization across two independent clinical cohorts.</p><p><strong>Methods: </strong>Skin prick test (SPT) results and serum total IgE levels from 226 participants were retrospectively analyzed from two cross-sectional cohorts (2005-2006 and 2011-2012) at a tertiary referral center. Sensitization patterns and polysensitization were compared by sex and diagnosis. Multivariable logistic regression models were used to assess independent associations, adjusting for age, diagnosis, and cohort.</p><p><strong>Results: </strong>In the earlier cohort, females exhibited higher total IgE levels and a greater prevalence of allergic rhinitis, whereas asthma predominated among males. In the later cohort, males demonstrated broader sensitization profiles and higher polysensitization rates. After adjustment for age and diagnosis, sex remained independently associated with polysensitization (aOR 0.41, 95% CI 0.17-0.99, p=0.048), while cohort differences were not statistically significant. House dust mites were the most prevalent allergen in both cohorts.</p><p><strong>Conclusions: </strong>Sex significantly influences aeroallergen sensitization patterns in clinical populations. The observed cohort differences appear to be largely explained by demographic and diagnostic composition rather than definitive temporal trends.</p>","PeriodicalId":7536,"journal":{"name":"Allergologia et immunopathologia","volume":"54 4","pages":"63-73"},"PeriodicalIF":2.1,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148417622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pediatric drug allergy: a retrospective analysis of clinical features, laboratory parameters, and systemic inflammation indices.","authors":"Filiz Demir Şahin, Ozan Kapçay, Mehmet Kılıç","doi":"10.15586/aei.v54i4.1587","DOIUrl":"https://doi.org/10.15586/aei.v54i4.1587","url":null,"abstract":"<p><strong>Background: </strong>This study aimed to investigate the potential utility of hematological parameters and systemic inflammatory indices as predictive biomarkers in pediatric patients with drug hypersensitivity reactions (DHRs).</p><p><strong>Methods: </strong>We performed a retrospective review of medical records of children presenting to the Pediatric Allergy and Immunology Clinic at Fırat University Hospital, Turkey, between January 2019 and July 2025 with suspected DHRs. Demographic characteristics, clinical manifestations, reaction phenotypes, complete blood counts, and total immunoglobulin E (IgE) levels were analyzed. Inflammatory indices, such as neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), eosinophil-to-lymphocyte ratio (ELR), and systemic immune-inflammation index (SII), were calculated subsequently.</p><p><strong>Results: </strong>Among the 45 children included, drug allergy was confirmed in 14 (31.1%) children. Total IgE levels did not differ significantly between groups (P = 0.712). Monocyte counts were significantly higher in the patient group (P = 0.039), whereas eosinophil counts were elevated in the control group (P = 0.026). Lymphocyte (P = 0.002) and basophil counts (P = 0.002) were significantly lower in the patient cohort. No significant differences were observed in neutrophil or platelet counts. Regarding inflammatory indices, NLR (P = 0.007), PLR (P = 0.006), and SII (P = 0.007) were significantly increased in the patient group, whereas ELR did not differ significantly (P = 0.073).</p><p><strong>Conclusion: </strong>In this small, single-center cohort (n = 45; confirmed DHR, n = 14), higher NLR, PLR, and SII were observed among children with confirmed DHRs. These preliminary findings suggest that readily available hematological indices may aid hypothesis generation and tentative risk stratification; however, they should be interpreted cautiously and require confirmation in larger prospective studies.</p>","PeriodicalId":7536,"journal":{"name":"Allergologia et immunopathologia","volume":"54 4","pages":"87-92"},"PeriodicalIF":2.1,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148417863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Delayed-type drug hypersensitivity reactions in a tertiary adult allergy clinic: A 5-year cohort study.","authors":"Makbule Seda Bayrak Durmaz, Begüm Görgülü Akın, Fikriye Kalkan, Betül Özdel Öztürk, Şadan Soyyiğit","doi":"10.15586/aei.v54i4.1630","DOIUrl":"10.15586/aei.v54i4.1630","url":null,"abstract":"<p><strong>Background and objectives: </strong>Delayed-type drug hypersensitivity reactions (DHRs) range from maculopapular eruptions to severe cutaneous adverse reactions (SCARs). Provocation tests are unsafe in SCARs, so diagnosis depends on history, making regional data important for identifying high-risk drugs. This study aimed to retrospectively assess the clinical features and test results of patients with delayed-type DHRs in our clinic.</p><p><strong>Materials and methods: </strong>Adults ≥18 years with DHRs, evaluated at our clinic between 2019 and 2025, were included in this retrospective observational study. Patients with Types I-III reactions or incomplete records were excluded. Eligible cases were identified through retrospective review of medical records. Clinical data, laboratory findings, and patch and/or drug provocation test results were obtained from medical files.</p><p><strong>Results: </strong>Thirty-three patients were included, of which 57.6% were females, and the median age was 40 years (19-70). The most common phenotype was maculopapular exanthem (n = 15, 45.5%), followed by fixed drug eruption (FDE) (n = 8, 24.2%). Seven patients (21.2%) had SCAR, including toxic epidermal necrolysis (TEN, n = 3), Stevens-Johnson syndrome (SJS, n = 1), SJS/TEN overlap (n = 1), drug-related eosinophilia and systemic symptoms (n = 1), and generalized bullous FDE (n = 1). Six patients (18.2%) required hospitalization, four of whom were managed in an intensive care or burn unit. Seventeen patients (51.5%) had a single likely culprit drug, while the remaining patients were taking multiple medications. Antimicrobials (41.3%), particularly beta-lactam antibiotics, and nonsteroidal anti-inflammatory drugs (NSAIDs, 29.3%), were the most frequently implicated drug groups. Nine patients underwent diagnostic testing (patch testing n = 6, delayed intradermal testing n = 3), with four positive results.</p><p><strong>Conclusions: </strong>Antibiotics, especially beta-lactam antibiotics and NSAIDs, were the leading culprit drugs. Polypharmacy complicates culprit identification, particularly in SCAR cases, underscoring the need for cautious prescribing and avoidance of unnecessary medications.</p>","PeriodicalId":7536,"journal":{"name":"Allergologia et immunopathologia","volume":"54 4","pages":"1-10"},"PeriodicalIF":2.1,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148417617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serum EDN as a novel biomarker for severe eosinophilic adult asthma.","authors":"Şeyma Özden, Aysun Aynacı, İsmet Bulut, Şebnem Korkmaz","doi":"10.15586/aei.v54i4.1690","DOIUrl":"https://doi.org/10.15586/aei.v54i4.1690","url":null,"abstract":"<p><strong>Background: </strong>Eosinophilic inflammation is a major pathophysiological mechanism in severe asthma (SA). However, a reliable serum biomarker reflecting this type of inflammation has not yet been identified. Therefore, in this study, we aimed to investigate whether serum levels of eosinophil-derived neurotoxin (EDN) could serve as a biomarker for predicting the diagnosis of SA in adult patients with asthma.</p><p><strong>Methods: </strong>A total of 89 patients, including 52 with SA and 37 with nonsevere asthma (NSA), were included in the study, all having PBEC ≥ 150 cells/µL. The relationships between serum EDN and serum eosinophilic cationic protein (ECP) levels with peripheral blood eosinophil count (PBEC), as well as with clinical and demographic parameters, were assessed. In addition, the clinical validity of serum EDN and PBEC levels in predicting the SA phenotype was evaluated.</p><p><strong>Results: </strong>A correlation analysis among PBEC, serum EDN, and serum ECP levels revealed statistically significant positive correlations: between PBEC and serum ECP (<i>p</i><0.001), PBEC and serum EDN (<i>p</i><0.001), and serum ECP and serum EDN (<i>p</i>=0.002). Serum EDN and PBEC levels were significantly higher in the SA group compared to the NSA group (225.40 [0.001-588.76] vs. 380.05 [0.001-1920.45], <i>p</i><0.001; 290 [160-820] vs. 335 [170-2070], <i>p</i>=0.003, respectively). Regarding spirometric parameters, FEV₁ (mL and %), FVC (mL and %), and FEF_25-75 (mL and %) values were significantly lower in the SA group compared to the NSA group. In the receiver operating characteristic (ROC) curve analysis evaluating the predictive value of serum EDN levels for identifying the SA phenotype, a sensitivity of 69% was observed. In univariate analysis, both serum EDN and PBEC levels were significantly associated with SA. However, multivariate analysis demonstrated that only serum EDN levels remained a statistically significant independent predictor of the SA phenotype.</p><p><strong>Conclusions: </strong>Serum EDN emerged as an independent predictor of the SA phenotype and demonstrated superior diagnostic performance compared with conventional eosinophilic markers. These findings highlight its potential as a promising biomarker for identifying SA and reflecting underlying type 2 airway inflammation.</p>","PeriodicalId":7536,"journal":{"name":"Allergologia et immunopathologia","volume":"54 4","pages":"74-80"},"PeriodicalIF":2.1,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148417821","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Benralizumab is effective in severe asthma with CRS, regardless of demographic and clinical basal outcomes.","authors":"Diana Betancor Perez, Marcela Valverde-Monge, Ana Rosado, Mar Gandolfo-Cano, Teresa Robledo Echarren, María Del Mar Moro-Moro, María Del Mar Reaño Martos, Rafael Pineda-Pineda, Dario Antolin-Amérigo, Ines Torrado, Maria Vazquez de la Torre, Remedios Cardenas, Ismael García-Moguel, Javier Domínguez-Ortega","doi":"10.15586/aei.v54i4.1449","DOIUrl":"10.15586/aei.v54i4.1449","url":null,"abstract":"<p><p>Severe eosinophilic asthma (SEA) frequently coexists with chronic rhinosinusitis (CRS), with or without nasal polyps (CRSwNP/CRSsNP), exacerbating disease burden. The Sino-Nasal Outcomes Test (SNOT-22) assesses quality of life in CRS patients, but the impact of benralizumab on nasal symptoms remains controversial. This retrospective multicenter study analyzed SNOT-22 changes after 12 months of benralizumab treatment in SEA patients with comorbid CRS from the AUTOBENRA study, including data from nine Spanish hospitals. Among 121 screened SEA patients, 72 (59.5%) had CRS, with 31 providing complete SNOT-22 data pre- and posttreatment. Subjects were predominantly female (74.2%), with a mean age of 56.4 ± 13.8 years. Most (85%) had CRSwNP, 71% reported anosmia, and 67.6% had undergone functional endoscopic sinus surgery (FESS) (mean: 2.3 ± 1.7 surgeries). The baseline SNOT-22 score averaged 55.7 ± 24.6 points. After 12 months, 21 (67.7%) achieved a minimal clinically important difference (MCID; ≥12 points). Notably, anosmic subjects were more likely to achieve the MCID (82% vs 33%; P = 0.005). No significant correlations emerged between SNOT-22 improvement and demographic, clinical, or biomarker profiles.These findings suggest that benralizumab significantly improves quality of life in SEA patients with CRS, particularly those with anosmia, regardless of baseline characteristics or biomarker levels.</p>","PeriodicalId":7536,"journal":{"name":"Allergologia et immunopathologia","volume":"54 4","pages":"162-166"},"PeriodicalIF":2.1,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148417626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}